References
1. Bernstein JA, Singh U, Rao MB, Berendts K, Zhang X, Mutasim D. Treatment of chronic spontaneous urticaria with benralizumab: Report of primary endpoint per-protocol analysis and exploratory endpoints. Allergy.2021;76(4):1277-1280.
2. Bernstein JA, Singh U, Rao MB, Berendts K, Zhang X, Mutasim D. Benralizumab for Chronic Spontaneous Urticaria. N Engl J Med.2020;383(14):1389-1391.
3. Gimenez-Arnau A, Curto-Barredo L, Nonell L, et al. Transcriptome analysis of severely active chronic spontaneous urticaria shows an overall immunological skin involvement. Allergy.2017;72(11):1778-1790.
4. Ghosh D, Ding L, Sivaprasad U, et al. Multiple Transcriptome Data Analysis Reveals Biologically Relevant Atopic Dermatitis Signature Genes and Pathways. PLoS One. 2015;10(12):e0144316.
5. Ghosh D, Ding L, Bernstein JA, Mersha TB. The Utility of Resolving Asthma Molecular Signatures Using Tissue-Specific Transcriptome Data.G3 (Bethesda). 2020;10(11):4049-4062.
6. Murakami M, Taketomi Y. Secreted phospholipase A2 and mast cells.Allergol Int. 2015;64(1):4-10.
7. Lopez-Dee Z, Pidcock K, Gutierrez LS. Thrombospondin-1: multiple paths to inflammation. Mediators Inflamm. 2011;2011:296069.
8. Chaves de Souza JA, Nogueira AV, Chaves de Souza PP, et al. SOCS3 expression correlates with severity of inflammation, expression of proinflammatory cytokines, and activation of STAT3 and p38 MAPK in LPS-induced inflammation in vivo. Mediators Inflamm.2013;2013:650812.
Table-1. Significantly enriched disease-relevant and treatment-relevant biological processes. (A) Processes associated with CSU lesional skin (compared to non-lesional skin) identified by enrichment analysis. Gene Ontology identifiers are shown within parentheses. Top significant processes have been shown with eosinophil chemotaxis (GO:0048245) and eosinophil migration (GO:0072677) were the two significant (adj. p-value = 2.016e-7 for both) biological processes associated with CSU that showed highest combined scores in enrichment analysis. (B) Processes associated with skin transcriptomes before vs. after benralizumab therapy.